Cargando…

2015 Review of Newly Approved Oncologic Therapies

Detalles Bibliográficos
Autores principales:	Medina, Patrick, Giordana, Monique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679039/ https://www.ncbi.nlm.nih.gov/pubmed/29152387

Ejemplares similares

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
por: Green, Angela K., et al.
Publicado: (2021)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision
por: Zhang, Yuqi, et al.
Publicado: (2022)

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021)

Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
por: Nix, Nancy M., et al.
Publicado: (2019)

Radiation Oncology reviewer acknowledgement 2015
por: Belka, Claus, et al.
Publicado: (2016)

Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects
por: Mohi-ud-din, Roohi, et al.
Publicado: (2023)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review
por: Peuskens, J., et al.
Publicado: (2014)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
por: Lu, Dan, et al.
Publicado: (2016)

Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
por: Martins, Alexander C., et al.
Publicado: (2022)

Journal of Hematology & Oncology reviewer acknowledgement 2015
por: Liu, Delong
Publicado: (2016)

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
por: Macklis, Paul C., et al.
Publicado: (2020)

Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities
por: Feng, Catherine, et al.
Publicado: (2021)

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)

Does Industry‐Conducted All‐Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?
por: Suzuki, Akiyuki, et al.
Publicado: (2019)

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
por: Talpaz, Moshe, et al.
Publicado: (2020)

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
por: Dockery, LE, et al.
Publicado: (2017)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
por: Tateo, Valentina, et al.
Publicado: (2023)

Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”
por: Chabner, Bruce A.
Publicado: (2017)

A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions
por: Xiao, Jim J., et al.
Publicado: (2017)

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
por: Gao, Lu-Hua, et al.
Publicado: (2021)

Medicare Spending on Drugs With Accelerated Approval, 2015-2019
por: Rome, Benjamin N., et al.
Publicado: (2021)

Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned
por: Ro, Sunhee K., et al.
Publicado: (2023)

Radiation Oncology Device Approval in the United States and Canada
por: Beers, Craig A, et al.
Publicado: (2019)

Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
por: Durães, Fernando, et al.
Publicado: (2019)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Side Effects of Cytokines Approved for Therapy
por: Baldo, Brian A.
Publicado: (2014)

The global landscape of approved antibody therapies
por: Lyu, Xiaochen, et al.
Publicado: (2022)

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022)

Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology
por: Kurtin, Sandra E., et al.
Publicado: (2020)

Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease
por: Di Luca, Daniel Garbin, et al.
Publicado: (2022)

Repurposing approved drugs for cancer therapy
por: Schein, Catherine H
Publicado: (2021)

Gene therapy for cancer: regulatory considerations for approval
por: Husain, S R, et al.
Publicado: (2015)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Contemporary oncology trials, drug approvals and the physician-patient relationship
por: Schnog, John-John B., et al.
Publicado: (2022)

Single-arm trials for domestic oncology drug approvals in China
por: Zhang, Hong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e2dm8laauufuupag159ht4qndv